Atyr Pharma Inc Stock Price, News & Analysis

aTyr Pharma (NASDAQ:ATYR) has announced the completion of the last patient visit in its Phase 3 EFZO-FIT™ study for efzofitimod in pulmonary sarcoidosis patients. The study, which is the first-ever global Phase 3 and largest interventional sarcoidosis trial, enrolled 268 subjects across multiple centers in the US, Europe, Japan, and Brazil.

The 52-week study evaluates two dosing regimens (3.0 mg/kg and 5.0 mg/kg) against placebo, administered monthly for 12 doses. The trial's primary endpoint focuses on steroid reduction, with secondary endpoints measuring sarcoidosis symptoms and lung function. Topline results are expected in Q3 2025.

Efzofitimod, a first-in-class biologic immunomodulator, targets interstitial lung disease by selectively modulating activated myeloid cells through neuropilin-2, potentially offering a safer alternative to current steroid-based treatments.

aTyr Pharma (Nasdaq: ATYR), a clinical stage biotechnology company, announced its upcoming addition to both the Russell 2000® Index and Russell 3000® Index, effective after market close on June 27, 2025.

The Russell 3000® Index serves as a key benchmark for the U.S. equity market, tracking the 3,000 largest publicly traded U.S. companies, while the Russell 2000® Index specifically focuses on small-cap companies. This inclusion, which lasts for one year, will result in automatic inclusion in corresponding growth and value style indexes.

aTyr Pharma (ATYR) announced promising interim results from its Phase 2 EFZO-CONNECT study evaluating efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD). The analysis of 8 patients at 12 weeks showed that 3 out of 4 efzofitimod-treated patients with diffuse SSc-ILD demonstrated clinically important improvement in modified Rodnan Skin Score (mRSS). The drug was generally safe and well-tolerated across all doses, with no treatment-related serious adverse events. The study is evaluating 270mg and 450mg doses against placebo in up to 25 patients, with a primary focus on pulmonary, cutaneous, and systemic manifestations. Preliminary data showed improvements in inflammatory and disease biomarkers. Efzofitimod has received FDA and EU orphan drug designations and FDA Fast Track status for SSc.

aTyr Pharma (NASDAQ: ATYR), a clinical stage biotech company, has announced its participation in three upcoming investor conferences in May-June 2025. CEO Sanjay S. Shukla will present at the RBC Capital Markets Global Healthcare Conference (May 21), Piper Sandler Virtual Lung Symposium (May 27), and Jefferies Global Healthcare Conference (June 5). The presentations at RBC and Jefferies will be available via webcast on the company's website for 90 days, with one-on-one investor meetings available at these events. aTyr focuses on developing first-in-class medicines from tRNA synthetase biology, with their lead candidate efzofitimod targeting interstitial lung disease treatment.

aTyr Pharma presented three posters on efzofitimod at the ATS 2025 International Conference, revealing significant insights about pulmonary sarcoidosis and their ongoing Phase 3 EFZO-FIT™ study. The research shows that approximately 158,900 people in the U.S. have pulmonary sarcoidosis with parenchymal involvement, with 30,000 new cases diagnosed annually. Key findings reveal that 75% of diagnosed patients require steroid treatment, and most patients on second-line therapies continue glucocorticoid use. The Phase 3 trial has enrolled 268 patients, with 264 dosed, representing a moderate to severe patient population. The mean baseline oral corticosteroid dose was 10.55 mg, with 38.3% of patients on steroid-sparing immunosuppressants. The disease disproportionately affects women and Black individuals, with mortality rates among patients aged 65-74 being nearly double that of the general population (15.4% vs 8.0%).

aTyr Pharma (NASDAQ: ATYR), a clinical-stage biotech company, has granted stock options to two new employees as part of their inducement compensation package. The options allow the purchase of 36,200 shares of common stock at $3.00 per share, matching the closing price on May 15, 2025. These grants, made under the aTyr Pharma 2022 Inducement Plan, follow Nasdaq Listing Rule 5635(c)(4).

The options vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over three years, contingent on continued employment. aTyr focuses on developing first-in-class medicines from its tRNA synthetase platform, with their lead candidate efzofitimod targeting interstitial lung disease treatment.

aTyr Pharma (NASDAQ: ATYR) has advanced ATYR0101 to IND candidate stage for treating pulmonary fibrosis. The drug candidate will be presented at the American Thoracic Society 2025 Respiratory Innovation Summit in San Francisco. ATYR0101 is a fusion protein derived from aspartyl-tRNA synthetase that targets LTBP-1 to induce myofibroblast cell death, which are key cells in fibrosis progression.

The company's preclinical data suggests ATYR0101 may have potential to reverse fibrosis, marking a significant advancement over current treatments that only slow disease progression. aTyr plans to file an IND application in the second half of 2026. This development builds on the clinical success of their lead therapy, efzofitimod, in interstitial lung disease.

aTyr Pharma (NASDAQ: ATYR) reported its Q1 2025 results and provided key updates on its clinical programs. The company's flagship Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis is progressing well, with topline data expected in Q3 2025. The study enrolled 268 patients across 85 centers in nine countries. The company's Phase 2 EFZO-CONNECT™ study for systemic sclerosis-related ILD continues enrollment, with interim data expected in Q2 2025. Financially, aTyr reported $78.8 million in cash and investments as of March 31, 2025, with R&D expenses of $11.8 million and G&A expenses of $4.0 million for Q1. The company appointed Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise and will present important data at the upcoming ATS 2025 International Conference.

aTyr Pharma presented promising preclinical data for their ATYR2810 antibody at the AACR Annual Meeting 2025 in Chicago. The research focuses on treating glioblastoma multiforme (GBM), an aggressive form of brain cancer.

Key findings show that ATYR2810, which targets neuropilin-2 (NRP2), demonstrated significant anti-tumor activity and improved survival rates in GBM models. The antibody proved effective both as a standalone treatment and when combined with anti-PD-1 therapies.

The research, conducted in collaboration with Stanford Medicine, revealed that ATYR2810 helps combat drug resistance by targeting immunosuppressive myeloid cells in the tumor microenvironment. The study used syngeneic tumor models, including the orthotopic CT-2A mouse model of GBM, showing enhanced anti-tumor immunity and increased overall survival.